Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Kobayashi, Mariko; Akuta, Norio; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Arase, Yasuji; Ikeda, Kenji; Hosaka, Tetsuya; Saitoh, Satoshi; Kobayashi, Masahiro; Someya, Takashi; Sato, Junko; Watabiki, Sachiyo; Miyakawa, Yuzo; Kumada, Hiromitsu

doi:10.1002/jmv.20504

Cited by 17 publications

(13 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies from Japan have also documented an association of HBV/A and HBV/C with chronic liver disease, while HBV/D was associated with asymptomatic HBV carriage [35,54] . In addition, HBV/A has also been reported to have increased potential of causing chronicity and HCC in sub-Saharan populations [55] .…”

Section: Discussionmentioning

confidence: 99%

Molecular Epidemiology and Clinical Significance of Hepatitis B Virus Genotypes, Core Promoter and Precore Mutations in Eastern India

Datta

Biswas²,

Chandra³

et al. 2008

Intervirology

View full text Add to dashboard Cite

Objectives: This unmatched case-control study aimed at determining the molecular epidemiology and clinical significance of HBV genotypes, core promoter (CP) and precore (PC) mutations in Eastern India. Methods: Serological, biochemical and molecular assays were used to examine antigens, ALT, genotypes, mutations and viremia among 106 inactive carriers and 183 chronic liver disease (CLD) patients. Results: Male gender (p < 0.001), HBeAg positivity (p = 0.050), high ALT (p < 0.001), high viremia (p < 0.001), CP mutations (p < 0.001), and genotypes A (p < 0.001) and C (p = 0.027) were significantly associated with CLD. Subjects infected with genotypes A and C had significantly higher prevalence of BCP mutations (p < 0.001), and low incidence of PC mutation (p < 0.001 and p = 0.047, respectively). Prevalence of genotype D was significantly higher among subjects with history of familial/childhood jaundice, while genotypes A and C were frequent among subjects with possible percutaneous exposure. Conclusions: Significant differences in risk factors and disease manifestation do exist among patients infected with different HBV genotypes. Genotypes A and C are frequently found among chronic liver disease patients, while genotype D is associated with inactive HBeAg-negative infections. This evaluation of clinical relevance of HBV genotypes, mutations and risk factors may be useful in disease prognosis, management and prevention strategies.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Epidemiology and Clinical Significance of Hepatitis B Virus Genotypes, Core Promoter and Precore Mutations in Eastern India

Datta

Biswas²,

Chandra³

et al. 2008

Intervirology

View full text Add to dashboard Cite

show abstract

“…Since they are infected with HBV of foreign genotypes represented by genotype A [15,16] , genotyping HBV DNA in donors with de novo infection would be able to trace the route of transmission in them. There are serious ramifications for the HBV infection of genotype A in that it tends to become chronic even in the adulthood and persists in 1 10% [17] , and that it elicits HBV mutants resistant to lamivudine more early and frequently than infections with the other genotypes [18] . HCV infection tended to occur more frequently in women than men (2.77 vs. 1.08/100,000 person-years), in opposite to HBV infection (2.01 vs. 3.44/100,000 person-years).…”

Section: Discussionmentioning

confidence: 99%

Incidence Rates of Hepatitis B and C Virus Infections among Blood Donors in Hiroshima, Japan, during 10 Years from 1994 to 2004

et al. 2008

Self Cite

View full text Add to dashboard Cite

Objective: Although prevalence rates of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections have kept decreasing in blood donors, there is little information on incidence rates of these hepatitis viruses in Japan. Methods: During 10 years from June 1994 through April 2004, 418,269 inhabitants of Hiroshima, Japan, donated blood (1,409,465 units in total). They were screened for serum markers of HBV and HCV infections, and individuals who developed de novo infections were identified. Results: Infection with HBV occurred at a rate of 2.78 per 100,000 person-years (95% confidence interval: 1.78–4.14/100,000 person-years) and that with HCV at a rate of 1.86 per 100,000 person-years (95% confidence interval: 1.06–3.01/100,000 person-years). Residual risks of transmission by transfusions, based on the relationship risk [window period (estimated at 0.15 and 0.03 years in chimpanzees inoculated with minimum infectious doses for HBV and HCV, respectively) × incidence], were 1/243,000 for HBV and 1/1,960,000 for HCV infections. Conclusion: At present, incidence rates of HBV and HCV infections are extremely low in Japan.

show abstract

“…Recently, however, infection with genotype A has been increasing predominantly in young men with promiscuous homo-or hetero-sexual contacts [Kobayashi et al, , 2004Ogawa et al, 2002]. Infection with HBV genotype A can persist, even if contracted in adulthood, in about 10% of cases [Sherlock, 1987;Kobayashi et al, 2006]. These circumstances provided an opportunity to compare the efficacy and side effects of long-term lamivudine, among patients infected with HBV genotypes A, B, and C, in a single Hepatology Center in Metropolitan Tokyo.…”

Section: Introductionmentioning

confidence: 99%

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Kobayashi

Suzuki

Akuta

et al. 2006

Journal of Medical Virology

Self Cite

View full text Add to dashboard Cite

Response to lamivudine treatment longer than 1 year was compared in 15 patients persistently infected with hepatitis B virus (HBV) genotype A, 38 with genotype B, and 449 with genotype C. Patients with genotype A were younger (median age 37 [range 24-49] vs. 47 [24-67] or 44 [18-73], P = 0.015), possessed hepatitis B e antigen (HBeAg) more frequently (73% vs. 21% or 56%, P < 0.001) and HBV DNA in higher levels (8.6 [6.1-8.7] vs. 6.5 [<3.7-8.7] or 6.5 [<3.7-8.7] log genome equivalents (LGE)/ml, P = 0.024) than those with genotype B or C. During lamivudine, YMDD mutants (89% vs. 53% or 42%, P = 0.0001) and breakthrough hepatitis developed more often (47% vs. 21% or 29%, P = 0.023) in patients with genotype A than B or C. YMDD mutants elicited more frequently in patients with genotype A than B or C who were positive (82% [9/11] vs. 25% [2/8] or 48% [117/245], P = 0.037) or negative for HBeAg (75% [3/4] vs. 30% [9/30] or 33% [68/204], P = 0.003). HBeAg (hazard ratio 2.1 [95% confidence interval 1.53-2.92], P < 0.001) and genotype A (2.78 [1.08-7.12], P = 0.034) enhanced the emergence of YMDD mutants by the Cox proportional hazard model. The risk for breakthrough hepatitis was increased by the baseline alanine aminotransferase level <500 IU/L (2.56 [1.82-5.50], P = 0.018), HBeAg (2.11 [1.40-3.16], P < 0.001), cirrhosis (1.92 [1.24-2.97], P = 0.004) and HBV DNA > or =8.0 LGE/ml (1.57 [1.04-2.36], P = 0.03); it was influenced by genotypes only in patients with HBeAg. In conclusion, HBV genotypes help in predicting response to long-term lamivudine treatment and development of YMDD mutants in patients with chronic hepatitis B.

show abstract

Virological outcomes in patients infected chronically with hepatitis B virus genotype A in comparison with genotypes B and C

Cited by 17 publications

References 54 publications

Molecular Epidemiology and Clinical Significance of Hepatitis B Virus Genotypes, Core Promoter and Precore Mutations in Eastern India

Molecular Epidemiology and Clinical Significance of Hepatitis B Virus Genotypes, Core Promoter and Precore Mutations in Eastern India

Incidence Rates of Hepatitis B and C Virus Infections among Blood Donors in Hiroshima, Japan, during 10 Years from 1994 to 2004

Response to long‐term lamivudine treatment in patients infected with hepatitis B virus genotypes A, B, and C

Contact Info

Product

Resources

About